DISCOVERY criver.1

Transcription

1 DISCOVERY

2 WHY DO WE DO DISCOVERY? BECAUSE WE BELIEVE THERE IS A CURE. We define drug discovery as the ability to identify, evaluate and develop successful new therapeutics that treat human disease and improve our quality of life. Working closely with our partners, we help them make the critical go/no-go decisions that move drugs through the development process from the lab to the clinic, and ultimately to the patients who need them. Outsourcing in the preclinical drug development space is often driven by the need for specialized in vitro and in vivo models, as well as a preference for organizations that offer streamlined discovery services from target identification to safety and toxicity studies. Because we believe in the work our clients mission, we are driven to deliver the science and technologies that can best support their quest for a cure. Through our continued investments, we are unequaled in our ability to provide fully integrated services that allow our partners to discover and develop novel therapeutics in an efficient and cost-effective manner. Charles River is the preclinical CRO partner of choice with the therapeutic expertise, expansive capabilities, operational excellence and customer-centric flexibility that clients need to optimize their drug development programs. We are proud to have supported the development of more than half of the new molecular entities approved by the FDA in the last 2 years, a fact which gives clients the confidence to partner with us. Hailing from both major pharma and biotech companies, drug developers around the globe continue to choose Charles River as their trusted companion on the journey to market. 02

3 WHAT WE DO THE DRUG DISCOVERY PROCESS ONCOLOGY CNS END TO END INTEGRATED DRUG DISCOVERY Drug discovery is not a simple left to right progression. The path from target identification to clinical candidacy is marked by continuous iterations across the process. This reality demands a partner who can guide clients through repetitions and refinements at each stage. We combine industry-proven experience and broad capabilities in chemistry, biology and pharmacology to optimize our clients progress along their compound s unique drug discovery path. CHEMISTRY INFLAMMATION CV/METABOLISM In Vitro Capabilities Understanding target biology Complex biology: primary/patient derived Hit finding & compound libraries Crystallography, biophysics In vitro safety assessment Chemistry: medicinal, synthetic, process ADME/PK Pharmaceutics Therapeutic Areas Oncology CNS/pain Inflammation & Immunology CV & Metabolic Respiratory Rare & neglected disease Ocular Other BIOLOGY RESPIRATORY RARE DISEASE PHARMACOLOGY 04

4 HOW ARE WE DIFFERENT? Innovation. Discovery from Charles River is unlike any other preclinical CRO we are able to support dynamic drug discovery and development every step of the way. Our integrated multidisciplinary team is skilled across a wide range of disease areas and has access to the most advanced science and latest technologies through our continued investment in instrumentation and education. Our scientists publish and collaborate with colleagues in their fields, and share their work with the global community. Committed to advancing research, we forge the academic partnerships that fuel innovation and work to support our partners search for critical funding. Efficiency. Always on the cutting edge, our facilities feature state-of-the-art equipment, much of which is highly customized and often superior to commercially available options. Moreover, the streamlined nature of our extensive capabilities creates greater cost efficiencies for more traditional services. For example, our translational imaging capabilities provide us with more information than traditional non-invasive imaging. Richer, more relevant data optimizes the use of resources and improves study outcomes. Collaboration. With discovery specialists located around the globe, we partner with organizations large and small across pharma, biotech and academia, and currently support over a hundred integrated drug discovery programs. From stand-alone studies to complete programs, we offer flexible business models tailored to suit the unique needs of our clients. 06

5 OUR CAPABILITIES START WITH OUR PEOPLE 650+ SCIENTISTS WITH: More than 300 patents at Charles River Thousands of peer-reviewed publications Client Services Account Managers/ Specialists Study Directors OUR TEAMS CONTRIBUTE TO: Over 1000 in vivo studies per year Over 100 drug discovery programs per year YOUR CHARLES RIVER SUPPORT TEAM Client It s our job to design molecules that have the best chances of going all the way through that pipeline to the clinic. A lot of what we do is new science you can t read it in the literature and we are breaking new ground all the time. Site Heads & Department Heads Scientists Program Managers Research Associates & Technicians 08

6 DISCOVERY FROM CHARLES RIVER BY THE NUMBERS Disease Area Inflammation No. of Candidates 13 Preclinical Phase I Phase IIa Phase IIb Phase III Registration CHEMOKINE, INTEGRIN, GPCR, CYTOKINE, KINASE, ENZYME Respiratory 24 GPCR, PROTEASE NHR, KINASE >60 development candidates in the past 15 years At least 5 candidates per year for the last decade 29 clinical candidates More than 3,000 studies performed per year CNS 6 Metabolic disease 4 Oncology 12 Anti-bacterial Anti-viral Cardiovascular 2 Secretory gastrointestinal GPCR, NHR ENZYME, KINASE, PROTEASE ENZYME, KINASE, PPI UNKNOWN PROTEASE ION CHANNEL ION CHANNEL 27% CANDIDATES HAVE PROGRESSED TO CLINICAL POC OR BEYOND Significantly better than the industry standard (12-24%) Additional 11 being progressed towards clinical PoC 10